Hemostemix Inc.: Hemostemix Announces Closing of Unit Private Placement
Hemostemix or the
Units ) announced on April 9, 2021, for gross proceeds of $440,031.90 (the
Offering ). The Offering consisted of the issuance of an aggregate of 1,257,234 Units at a price of $0.35 per Unit. Each Unit consists of one common share in the capital of the Company (
Common Share ) and one transferable common share purchase warrant (
Warrant ), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.40 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Hemostemix Inc.: Hemostemix Announces Warrant Repricing and Extension
Hemostemix or the
Company ) is pleased to announce that it has, subject to TSX Venture Exchange Approval, repriced to $0.55 each, and extended the exercise period for two years, the Warrants expiring May 7, 2020 and May 28, 2020, subject to the accelerator provisions, such that the exercise period of Warrants will be reduced to thirty (30) days, if, for any ten consecutive trading days during the unexpired term of the Warrants, the weighted average closing price of the Company s listed shares achieves or exceeds the price of 120% of the applicable exercise price ($0.66). The 30-day expiry period commences on the day the Company either (i) disseminates a press release, or (ii) sends a written notice to the holders of the Warrants advising of the commencement of the exercise period.
Calgary, Alberta (Newsfile Corp. - April 30, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that, with the last patient follow up
Hemostemix Inc.: Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list
Hemostemix or the
Company ) is pleased to announce the completion of the Phase II Clinical Trial subject follow up, as the 65
th (final) subject has completed their last follow-up visit. With subject follow up now completed the Company is shifting its focus to completing the data analyses and reporting associated with finalizing their Phase II Clinical Trial. In addition, the Company has contracted two additional clinical research associates to assist with the completion of the source document verification process. The entry of all subjects information into the clinical trial data base and source document verification processes are ongoing and this is a crucial preliminary step in finalizing the Phase II Clinical Trial.
Hemostemix Inc : Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.